Evolus Inc. (EOLS)
EOLS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1570562/000162828026014001/0001628280-26-014001-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | EOLS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001570562 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $297.2M |
| Net income | -$51.6M |
| Operating income | -$32.7M |
| Net margin | -17.4% |
| Operating margin | -11.0% |
| Revenue growth | +11.6% |
| Cash | $53.8M |
| Total assets | $225.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $41.7M cash; operating cash flow -$661K a quarter. | Report 2026-09-30 |
| Shares outstanding | 66,188,366 (2026-10-30); 64,819,784 a year earlier; 57,150,722 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-06-05 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Irvine, California, United States | PCAOB Form AP 2026-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $1.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $78.0M | -$12.5M | -$1.9M | $41.7M | $156.9M | $325.5M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $84.1M | -$8.1M | -$3.6M | $45.2M | $156.7M | $316.5M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $73.1M | -$10.7M | -$10.0M | $49.8M | $156.4M | $301.8M | 10-Q 2026-05-04 |
| Q4 2025 2025-12-31 | $90.3M | $130K | $12.8M | $53.8M | $146.1M | $297.2M | 10-K 2026-03-03 |
| Q3 2025 2025-09-30 | $69.0M | -$15.7M | -$14.7M | $43.5M | $145.8M | $285.8M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $69.4M | -$17.1M | -$24.8M | $61.7M | $145.5M | $277.9M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $68.5M | -$18.9M | -$15.6M | $67.9M | $121.8M | $275.5M | 10-Q 2026-05-04 |
| Q4 2024 2024-12-31 | $78.9M | -$6.8M | $4.8M | $87.0M | $121.5M | $266.3M | 10-K 2026-03-03 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-06-05 |
| Latest annual report | 10-K | 2026-03-03 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 558 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.3% |
| 1 month | -7.3% |
| 3 months | -13.2% |
| Year to date | +4.7% |
| 1 year | -5.6% |
| From 52-week high | -25.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ASMB | Assembly Biosciences Inc. | $21.29 | +0.80% | $436.0M |
| ARVN | Arvinas Inc. | $6.77 | -0.73% | $443.3M |
| BLSM | BlossomHill Therapeutics Inc. | $13.65 | -2.64% | $433.9M |
| CTMX | CytomX Therapeutics Inc. | $1.99 | -2.70% | $432.7M |
| MPLT | MapLight Therapeutics Inc. | $6.90 | -4.83% | $446.9M |
| DMAC | DiaMedica Therapeutics Inc. | $8.33 | -5.23% | $449.5M |
| AVTX | Avalo Therapeutics Inc. | $7.37 | -5.03% | $426.2M |
| OVID | Ovid Therapeutics Inc. | $2.40 | -5.51% | $453.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier